Nesiritide Acutely Increases Pulmonary and Systemic Levels of Nitric Oxide in Patients With Pulmonary Hypertension

Journal of Cardiac Failure

Volumn 12, Issue 7, 2006, Pages 507-513

  Khush, Kiran K ^a   De Marco, Teresa ^a   Vakharia, Kalpesh T ^a   Harmon, Cynthia ^b   Fineman, Jeffrey R ^b   Chatterjee, Kanu ^a   Michaels, Andrew D ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF UTAH   (United States)

Author keywords

Natriuretic peptides; Nitric oxide; Pulmonary hypertension; Vasodilator

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CYCLIC GMP; NESIRITIDE; NITRIC OXIDE; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; DRUG EFFECT; FEMALE; HEART CATHETERIZATION; HUMAN; LUNG BLOOD VESSEL; LUNG CAPILLARY PRESSURE; LUNG VASCULAR RESISTANCE; MALE; PH; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION;

ADULT; AGED; ARTERIES; CAPILLARIES; COHORT STUDIES; CYCLIC GMP; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; NATRIURETIC AGENTS; NATRIURETIC PEPTIDE, BRAIN; NITRIC OXIDE; PROSPECTIVE STUDIES; PULMONARY ARTERY; PULMONARY WEDGE PRESSURE; VASCULAR RESISTANCE; VASODILATOR AGENTS;

EID: 33748100374     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2006.05.004     Document Type: Article

References (30)

1. Mikhail G., Chester A.H., Gibbs J.S., Borland J.A., Banner N.R., and Yacoub M.H. Role of vasoactive mediators in primary and secondary pulmonary hypertension. Am J Cardiol 82 (1998) 254-255
2. Kaneko F.T., Arroliga A.C., Dweik R.A., Comhair S.A., Laskowski D., Oppedisano R., et al. Biochemical reaction products of nitric oxide as quantitative markers of primary pulmonary hypertension. Am J Respir Crit Care Med 158 (1998) 917-923
3. Giaid A., and Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 333 (1995) 214-221
4. Giaid A., Yanagisawa M., Langleben D., Michel R.P., Levy R., Shennib H., et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 328 (1993) 1732-1739
5. Ahluwalia A., MacAllister R.J., and Hobbs A.J. Vascular actions of natriuretic peptides. Cyclic GMP-dependent and -independent mechanisms. Basic Res Cardiol 99 (2004) 83-89
6. Lewicki J.A., and Protter A.A. Natriuretic peptide family. In: Laragh J.H., and Brenner B.M. (Eds). Hypertension, pathophysiology, diagnosis, and management (1995), Raven, New York 1029-1053
7. Protter A.A., Wallace A.M., Ferraris V.A., and Weishaar R.E. Relaxant effect of human brain natriuretic peptide on human artery and vein tissue. Am J Hypertens 9 (1996) 432-436
8. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 287 (2002) 1531-1540
9. van der Zander K., Houben A.J., Kroon A.A., De Mey J.G., Smits P.A., and de Leeuw P.W. Nitric oxide and potassium channels are involved in brain natriuretic peptide induced vasodilatation in man. J Hypertens 20 (2002) 493-499
10. Kubo M., Nakaya Y., Matsuoka S., Saito K., and Kuroda Y. Atrial natriuretic factor and isosorbide dinitrate modulate the gating of ATP-sensitive K+ channels in cultured vascular smooth muscle cells. Circ Res 74 (1994) 471-476
11. Price J.M., and Hellermann A. Inhibition of cGMP mediated relaxation in small rat coronary arteries by block of CA++ activated K+ channels. Life Sci 61 (1997) 1185-1192
12. Michaels A.D., Chatterjee K., and De Marco T. Effects of intravenous nesiritide on pulmonary vascular hemodynamics in pulmonary hypertension. J Card Fail 11 (2005) 425-431
13. Schiller N.B., Shah P.M., Crawford M., DeMaria A., Devereux R., Feigenbaum H., et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 2 (1989) 358-367
14. Maack T. Role of atrial natriuretic factor in volume control. Kidney Int 49 (1996) 1732-1737
15. Kone B.C. Molecular biology of natriuretic peptides and nitric oxide synthases. Cardiovasc Res 51 (2001) 429-441
16. Levin E.R., Gardner D.G., and Samson W.K. Natriuretic peptides. N Engl J Med 339 (1998) 321-328
17. Bolad I., and Delafontaine P. Endothelial dysfunction: its role in hypertensive coronary disease. Curr Opin Cardiol 20 (2005) 270-274
18. Kawashima S. The two faces of endothelial nitric oxide synthase in the pathophysiology of atherosclerosis. Endothelium 11 (2004) 99-107
19. Naseem K.M. The role of nitric oxide in cardiovascular diseases. Mol Aspects Med 26 (2005) 33-65
20. Higenbottam T.W., and Laude E.A. Endothelial dysfunction providing the basis for the treatment of pulmonary hypertension: Giles F. Filley lecture. Chest 114 (1998) 72S-79S
21. Chen Y.F., and Oparil S. Endothelial dysfunction in the pulmonary vascular bed. Am J Med Sci 320 (2000) 223-232
22. Madhani M., Scotland R.S., MacAllister R.J., and Hobbs A.J. Vascular natriuretic peptide receptor-linked particulate guanylate cyclases are modulated by nitric oxide-cyclic GMP signalling. Br J Pharmacol 139 (2003) 1289-1296
23. Papapetropoulos A., Rudic R.D., and Sessa W.C. Molecular control of nitric oxide synthases in the cardiovascular system. Cardiovasc Res 43 (1999) 509-520
24. Govers R., and Rabelink T.J. Cellular regulation of endothelial nitric oxide synthase. Am J Physiol Renal Physiol 280 (2001) F193-F206
25. Calderone A. The therapeutic effect of natriuretic peptides in heart failure; differential regulation of endothelial and inducible nitric oxide synthases. Heart Fail Rev 8 (2003) 55-70
26. de Frutos S., Saura M., Rivero-Vilches F.J., Rodriguez-Puyol D., and Rodriguez-Puyol M. C-type natriuretic peptide decreases soluble guanylate cyclase levels by activating the proteasome pathway. Biochim Biophys Acta 1643 (2003) 105-112
27. Ferrero R., Rodriguez-Pascual F., Miras-Portugal M.T., and Torres M. Nitric oxide-sensitive guanylyl cyclase activity inhibition through cyclic GMP-dependent dephosphorylation. J Neurochem 75 (2000) 2029-2039
28. Hobbs R.E., Miller L.W., Bott-Silverman C., James K.B., Rincon G., and Grossbard E.B. Hemodynamic effects of a single intravenous injection of synthetic human brain natriuretic peptide in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 78 (1996) 896-901
29. Marcus L.S., Hart D., Packer M., Yushak M., Medina N., Danziger R.S., et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation 94 (1996) 3184-3189
30. Badesch D.B., McLaughlin V.V., Delcroix M., Vizza C.D., Olschewski H., Sitbon O., et al. Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 43 (2004) 56S-61S